Skip to search formSkip to main contentSkip to account menu

MK-5172

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Quinoxalines

Narrower (1)

grazoprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Effi cacy and safety of grazoprevir ( MK-5172 ) and elbasvir ( MK-8742 ) in patients with hepatitis C virus and HIV co-infection ( C-EDGE CO-INFECTION ) : a non-randomised , open-label trial
Bonn University Hospital, Bonn, Germany (Prof J K Rockstroh MD); Chelsea and Westminster Hospital, London, UK (M Nelson MD… 
2014
2014
Efficacy and safety of MK-5172 and MK-8742 +/- ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response : Final results of the C-WORTHY Study (Parts A and B)
Efficacy and safety of MK-5172 and MK-8742 +/- ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous… 
2014
2014
Age and Gender Effects on the Pharmacokinetics of HCV NS5A Inhibitor MK-8742
Background: MK-8742 is a potent, once-daily, inhibitor of the hepatitis C virus (HCV) nonstructural protein NS5A being developed… 
2013
2013
Pharmacokinetic Interaction of HCV Protease Inhibitor MK-5172 and Ritonavir in Healthy subjects
2013
2013
Synthesis and Evaluation of New HCV NS3/4A Protease Inhibitors
The Hepatitis C virus infects an estimated 170 million people worldwide, and is the major cause of hepatitis, cirrhosis and liver… 
2010
2010
Safety and Antiviral Activity of MK-5172, a Novel HCV NS3/4a Protease Inhibitor with Potent Activity Against Known Resistance Mutants, in Genotype 1 and 3 HCV-Infected Patients
• MK-5172 is a novel, competitive inhibitor of the HCV NS3/4a protease with selective, potent in vitro activity against a broad… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)